Medication safety in brief

News
Article

The labeling for dextroamphetamine (Dexedrine, GlaxoSmithKline) was revised to include new warnings. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.

The labeling for dextroamphetamine (Dexedrine, GlaxoSmithKline) was revised to include new warnings. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.

Recently reported Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) Program results demonstrated that the rate of confirmed thrombotic cardiovascular (CV) events was similar between etoricoxib (Arcoxia, Merck) and diclofenac. Specifically, in the pre-specified "per-protocol" analysis of the primary end point, the relative risk of confirmed thrombotic CV events between etoricoxib and diclofenac was 0.95 (95% CI, 0.81–1.11).

In the MEDAL study, the incidence of discontinuations due to hypertension-related adverse events was significantly higher for etoricoxib compared with diclofenac. Also in the MEDAL study, the incidence of discontinuations due to edema-related adverse events was significantly higher only for etoricoxib 90 mg compared with diclofenac, and the incidence of adjudicated and confirmed cases of congestive heart failure trended higher only for etoricoxib 90 mg compared with diclofenac.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.